期刊文献+

人胃癌组织中突变型P53蛋白的积聚与多重耐药基因的表达

The relationship between mutant P53 accumulation and MDR-1 gene expression in gastric cancer
下载PDF
导出
摘要 目的 研究突变型P53蛋白在胃癌组织中的积聚对多重耐药基因的作用。方法 采用免疫组化法从蛋白水平检测胃癌组织的P53蛋白与多重耐药基因产物P-糖蛋白 (Pg蛋白 )水平。结果 46份胃癌组织标本中P53蛋白阳性率为60.87% ,Pg蛋白阳性率为73.91 %。在28份P53蛋白阳性表达中有23份 (82.15% )Pg蛋白表达阳性;18份P53蛋白阴性表达中9份 (50.00 % )为Pg蛋白表达阳性。P53蛋白和Pg蛋白表达阳性率具有相关性 (P<0.05) ,且P53蛋白、Pg蛋白表达与癌组织的分化类型亦有关。结论 P53蛋白在胃癌组织中的积聚与Pg蛋白异常表达有关 ,P53可能通过各种机制调控多重耐药基因的表达。 Objective To explore the relationship between mutant P53 and MDR-1 gene expression in gastric cancer.Methods Forty six surgical specimens of gastric cancer were examined the levels of P53 protein and p-glycoprotein(PgP) by immunohistochemical technique.Results In this study 28 of 46 samples (60.87%) were positive for P53, and 34 of 46 (73.91%) were positive for PgP.Pgp expression were detected in 23 of 28 P53-positive specimens, and in 9 of 18 P53-negative ones.There was a close correlation between P53 and PgP expression (P<0.05).And the expression of PgP and P53 was closely associated with histological differentiation of the carcinoma.Conclusion The results demonstrate that PgP expression is closely associated with P53 protein accummulation in human gastric cancer.
出处 《浙江医学》 CAS 2002年第12期718-720,共3页 Zhejiang Medical Journal
关键词 胃癌 突变型 P53蛋白 多重耐药基因 免疫组织化学 P-glycoprotein P53 Gastric cancer MDR-1
  • 相关文献

参考文献15

  • 1Gottesman MM, Pastan Ⅰ. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem, 1993, 62: 385.
  • 2Greenblatt MS, Bennett WP, Hollstein M. et al. Mutations in the p53 tuomr suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res, 1994, 54: 4855.
  • 3Wu GS,Ei DW.P53 and chemosen-sitivity (letter).Nat Med, 1996, 2: 255.
  • 4Hawkin DS,Demers GW,Galloway DA. Inactivation of P53 enhances sensitivity to multiple chemotherapeutic agents.Cancer Res, 1996,56:892.
  • 5Thottassery JV, Zametti GP, Aeimori K, et al. P53-dependent regulstion of the MDR gene expression causes selective resistance to chemothrapeutic agents.Proc Natl Acad Sci USA, 1997,94: 11037.
  • 6陈江浩,张洪新,黄学胜,王执民,刘锟,白建军.周围型肺癌CT征象与p53蛋白及增殖细胞核抗原表达间关系的研究[J].中华肿瘤杂志,1998,20(5):361-364. 被引量:30
  • 7Fisher CJ, Gillett CE, Vijte Ek B, et al. Problems with P53 immunohistoehemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer, 1994, 69: 26.
  • 8Sglke V, Heyden D. P-Glycoprotein: clinical significance and methods of analysis. Clin Lab Sci, 1995, 32(3): 221.
  • 9Liu Y, Hu M. P-Glycoprotein and bioavailability-implication of polymorphism. Clin Chem Lab Med, 2000, 38: 877.
  • 10贾立群,于莉莉,朱世杰,李佩文,浦生真纪夫.大肠癌培养细胞p53存在状态与化疗敏感性[J].中华肿瘤杂志,2000,22(5):389-390. 被引量:10

二级参考文献9

  • 1[1]Herzoy CE,Trepll JB,Mickley LA,et al.Various Methods of Analysis of mdr-1/P-Glycoprotein in Human Color Cancer Cell Lincs.Journal of National Cancer Institute,1992,84:711~716.
  • 2[2]J Sambrook EF Fritsch,T.Manitatis.Molecular Cloning Second Edition Cold Spring Harbor Labortorary Press,1989,7:54.
  • 3[3]Fisher GA,et al.The Modulation of Multidrug Resistance in the Mechanism and New Approach on drug Resistance of Cancer Cells.Cancer Res,1996,56:722.
  • 4[4]Kobayashi H,Dorai T,Holland JF,et al.Reveral of Drug Sensitivity in Multidrug Resistant Tumor Cells by an Mdrl(PGP)Ribozyme.Cancer Res,1994,34:1271.
  • 5[5]Warholm M.Guthenberg C,Vori Bahr C,et al.Glutathion Transferase from Human Liver.Methods Enzymol.1985.113:499~505.
  • 6刘进康,中华放射学杂志,1996年,30卷,15页
  • 7曹丹庆,全身CT诊断学,1996年,326页
  • 8Li Q J,Mol Carcinog,1997年,19卷,243页
  • 9Ishioka C,Nature Genetics,1993年,5卷,124页

共引文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部